Background Image
Previous Page  166 / 182 Next Page
Information
Show Menu
Previous Page 166 / 182 Next Page
Page Background

165

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

169

Mercadante S, Gatti A, Porzio G, Lo Presti C, Aielli F, Adile C, Casuccio A. Dosing fentanyl

buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.

Curr Med Res Opin 2012; 28(6): 963-968.

170

Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, Mangione S. Intravenous morphi-

ne for episodic-breakthrough pain in an acute palliative care unit: a confirmatory study.

J Pain Symptom Manage 2008; 35: 307-313.

171

Mercadante S, Maddaloni S, Roccella S, Salvaggio L. Predictive factors in advanced

cancer pain treated only by analgesics. Pain 1992; 50: 151-155.

172

Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, Ripamonti C, De

Conno F; Steering Committee of the European Association for Palliative Care (EAPC)

Research Network. Episodic (breakthrough) pain. Consensus conference of an Expert

Working Group of the European Association for Palliative Care. Cancer 2002; 94(3):

832-839.

173

Mercadante S, Radbruch L, Davies A, Poulain P, Sitte T, Perkins P, Colberg T, Camba MA.

A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for

the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.

Curr Med Res Opin 2009; 25(11): 2805-2815.

174

Mercadante S, Sapio M, Villari P. Suprascapular nerve block by catheter for breakt-

hrough shoulder cancer pain. Regional Anesthesia 1995; 20: 343-346.

175

Mercadante S, Villari P, Ferrera P, Bianchi M, Casuccio A. Safety and effectiveness of

intravenous morphine for episodic-breakthrough pain, using a fixed ratio with the oral

daily morphine dose. J Pain Symptom Manage 2004; 27: 352-359.

176

Mercadante S, Villari P, Ferrera P, Casuccio A, Mangione S, Intravaia G. Transmucosal

fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for

episodic-breakthrough pain. Br J Cancer 2007; 96: 1828-1833.

177

Mercadante S, Villari P, Ferrera P, Casuccio A. Optimization of opioid therapy for pre-

venting incident pain associated with bone metastases. Journal of Pain and Symptom

Management 2004; 28: 505-510.

178

Mercadante S, Villari P, Ferrera P, Mangione S, Casuccio A. The use of opioids for break-

through pain in acute palliative care unit by using doses proportional to opioid basal

regimen. Clin J Pain 2010; 26: 306-309.

179

Mercadante S. Breakthrough pain: on the road again. Eur J Pain 2009; 13: 329-430.

180

Mercadante S. Managing breakthrough pain. Curr Pain Headache Rep. 2011; 15(4):

244-249.

181

Mercadante S. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in

cancer patients. Expert Opin Pharmacother 2012; 13(6): 873-878.

182

Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs 2012; 72(2):

181-190.

183

Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the chal-

lenge of its dosing. Crit Rev Oncol Hematol. 2011; 80(3): 460-465.

Literaturverzeichnis